- Home
- PSTV vs ATHA Comparison
PSTV vs ATHA Comparison
Compare PSTV & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTV
- ATHA
- Stock Information
- Founded
- PSTV 1996
- ATHA 2011
- Country
- PSTV United States
- ATHA United States
- Employees
- PSTV N/A
- ATHA N/A
- Industry
- PSTV Medical/Dental Instruments
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- PSTV Health Care
- ATHA Health Care
- Exchange
- PSTV Nasdaq
- ATHA Nasdaq
- Market Cap
- PSTV 17.0M
- ATHA 14.8M
- IPO Year
- PSTV N/A
- ATHA 2020
- Fundamental
- Price
- PSTV $0.70
- ATHA $0.38
- Analyst Decision
- PSTV Strong Buy
- ATHA Buy
- Analyst Count
- PSTV 3
- ATHA 4
- Target Price
- PSTV $10.83
- ATHA $11.25
- AVG Volume (30 Days)
- PSTV 19.1M
- ATHA 191.8K
- Earning Date
- PSTV 08-22-2025
- ATHA 08-07-2025
- Dividend Yield
- PSTV N/A
- ATHA N/A
- EPS Growth
- PSTV N/A
- ATHA N/A
- EPS
- PSTV N/A
- ATHA N/A
- Revenue
- PSTV $5,206,000.00
- ATHA N/A
- Revenue This Year
- PSTV $8.26
- ATHA N/A
- Revenue Next Year
- PSTV $8.39
- ATHA N/A
- P/E Ratio
- PSTV N/A
- ATHA N/A
- Revenue Growth
- PSTV N/A
- ATHA N/A
- 52 Week Low
- PSTV $0.16
- ATHA $0.22
- 52 Week High
- PSTV $2.31
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- PSTV 60.91
- ATHA 49.40
- Support Level
- PSTV $0.45
- ATHA $0.36
- Resistance Level
- PSTV $0.90
- ATHA $0.40
- Average True Range (ATR)
- PSTV 0.12
- ATHA 0.04
- MACD
- PSTV 0.02
- ATHA -0.01
- Stochastic Oscillator
- PSTV 57.45
- ATHA 30.60
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.